bexarotene has been researched along with oxymorphone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Al-Madhagi, H; Alasmari, AF; Alasmari, F; Alharbi, M; Khan, M; Khan, MQ; Shahab, M; Wadood, A; Zeb, A; Zheng, G | 1 |
1 review(s) available for bexarotene and oxymorphone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for bexarotene and oxymorphone
| Article | Year |
|---|---|
Structure based virtual screening and molecular simulation study of FDA-approved drugs to inhibit human HDAC6 and VISTA as dual cancer immunotherapy.
Topics: Bexarotene; Blood Group Antigens; Early Detection of Cancer; Histone Deacetylase 6; Humans; Immunotherapy; Neoplasms; Oxymorphone | 2023 |